Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO) and Sarepta Therapeutics (SRPT)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTO) and Sarepta Therapeutics (SRPT) with bullish sentiments.

Aptose Biosciences (APTO)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aptose Biosciences, with a price target of $8.50. The company’s shares closed on Friday at $2.32.

Pantginis noted:

“Valuation and impediments to achieving price target. We reiterate our Buy and $8.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from both the CG-806 opportunity in AML and APTO-253 opportunity in AML and MDS. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -14.0% and a 30.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.25 average price target, which is a 212.5% upside from current levels. In a report issued on March 13, Oppenheimer also assigned a Buy rating to the stock with a $6 price target.

See today’s analyst top recommended stocks >>

Sarepta Therapeutics (SRPT)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Sarepta Therapeutics today and set a price target of $231. The company’s shares closed on Friday at $122.26.

Young observed:

“. We reiterate our Overweight rating and $231 Price Target. At a recent conference, Dr. Mendell presented data from the 4 DMD gene therapy patients after 9-months of follow-up. Additional NSAA and CK updates were included. Although unexpectedly released, these data reinforce our confidence in the functional durability of Sarepta’s micro-dystrophin gene therapy. We are not concerned by CK spikes in light of increased functionality and the protocol violations around resting CK-measurements that the company noted. We are not surprised that patients are more active since they may have lived with decreased activity due to DMD before treatment.”

According to TipRanks.com, Young is a 5-star analyst with an average return of 8.3% and a 49.1% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Puma Biotechnology.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $208.19, which is a 70.3% upside from current levels. In a report issued on March 11, H.C. Wainwright also maintained a Buy rating on the stock with a $267 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts